Accedi ai contenuti
Registrati »
Accedi ai contenuti
Registrati »
HomeLetteratura
Archivio

Background: As live expectancy and cancer incidence growing, polypharmacy in oncology patients is also increasing, raising the risk of developing potential drug–drug interactions. Objective: To assess the prevalence of clinically relevant potential drug–drug interactions among cancer patients who receive parenteral treatment at our outpatient clinic. Method Retrospective observational study which included randomly selected

Int J Clin Pharm (2019); DOI:  https://doi.org/10.1007/s11096-019-00910-7 /  Castro-Manzanares M, do Pazo-Oubiña F, Rodríguez-Rincón RM, et al.

Objective: To develop and pilot test a model in which a community-based clinical pharmacist was incorporated as part of a Medicare Annual Wellness Visit (AWV) to make deprescribing recommendations targeted at potentially inappropriate medications (PIMs) in the elderly. Setting: One family medicine Patient-centered medical home (PCMH) clinic in Buffalo, NY. Practice description:

Journal of the American Pharmacists Association 2019; DOI: https://doi.org/10.1016/j.japh.2019.09.011. /  Clark C, LaValley CM, Singh S, et al.

Objectives: To develop a pharmacist patient care services intervention reporting checklist to be used in conjunction with existing primary reporting tools. The tool should enhance consistent reporting of pharmacist patient care interventions. Tool use in pharmacist-patient care intervention reporting may increase: (1) likelihood for inclusion in higher order analyses and

Journal of the American Pharmacists Association 2019; (59)5:615-623. /  Clay P, Patrick G,et al.

Background: Oral chemotherapy agents are being prescribed more frequently in many cancer types. In-office dispensing of oral chemotherapy agents has demonstrated clinical benefits and also shown financial benefit to third-party payers. A previous publication estimated over $200,000 in cost savings annually from in-office dispensing solely from medications returned to stock

Journal of Oncology Pharmacy Practice 2019; 25(7), 1570–1575. /  Howard A, Ker J, McLain M, et al.

Background: Treatments for multiple myeloma (MM) have been rapidly evolving. Newly developed treatment regimens are likely to be more effective but also cost more than conventional therapies. Objective: We conducted a systematic review to compare the cost effectiveness of different classes of MM treatment. Methods: We searched the PubMed, MEDLINE, Web of

PharmacoEconomics 2019; DOI: https://doi.org/10.1007/s40273-019-00828 /  Fu, S., Wu, CF., Wang, M. et al.

Background: Collaboration between pharmacists, doctors, and nurses in outpatient treatment is beneficial; however, such services are limited in Japan due to the lack of a healthcare reimbursement fee for outpatient pharmacy services at outpatient clinic. Objective: We evaluated the impact of a service in which clinical pharmacists collaborated with an oncologist

Journal of Oncology Pharmacy Practice 2019; 25(7), 1558–1563. /  Suzuki, H, Kamata H, Sugama Y, et al.

Background: Recent years have witnessed the rapid evolution of therapies in chronic-phase chronic myeloid leukemia (CP-CML). To assess the efficacy and tolerability of all reported front-line treatments for patients with newly diagnosed CML, a multiple-treatments meta-analysis was performed, which accounted for both direct and indirect comparisons among those treatments. Methods: Primary

BMC Cancer 2019;19(1):849. /  Tang L, Zhang H, Peng YZ, et al.

Purpose: Pharmacists care for patients of all ages. Pediatric patients are not smaller versions of adults; thus, they provide a unique challenge to pharmacists. Basic components of patient assessment and considerations for medication dosing and administration for pediatric patients are reviewed here. Summary: Each pediatric patient is different, and physiological changes

Am J Health Syst Pharm 2019; 16;76(19):1463-1471. /  Eiland LS, Meyers RS

Chimeric antigen receptor (CAR) T cells targeting CD19 have emerged as a leading engineered T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The phase 1/2 clinical trials that led to US Food and Drug Administration approval excluded patients with central nervous system (CNS) involvement, due to strict eligibility criteria. Here, we report

Blood 2019;134(11):860-866. /  Frigault MJ, Dietrich J, Martinez-Lage M, et al.

The adoptive transfer of genetically engineered T cells expressing a chimeric antigen receptor (CAR) has shown remarkable results against B cell malignancies. This immunotherapeutic approach has advanced and expanded rapidly from preclinical models to the recent approval of CAR-T cells to treat lymphomas and leukemia by the Food and Drug

BioDrugs 2019 Sep 24. [Epub ahead of print] /  Roselli E, Frieling JS, Thorner K, et al.